8-K - FibroBiologics, Inc. Common Stock | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

FibroBiologics, Inc. implemented a 1-for-20 reverse stock split effective March 30, 2026, which proportionally reduced outstanding shares without altering stockholders' percentage ownership, except for fractional share adjustments.

Key Takeaways

1A 1-for-20 reverse stock split became effective on March 30, 2026, converting every 20 shares into one share.

2The CUSIP number for the Common Stock changed to 31573L204, while the trading symbol remains 'FBLG'.

3No fractional shares will be issued; any resulting fractional shares will be rounded up to the nearest whole share.

4The reverse stock split proportionally adjusts shares available under the equity incentive plan and the exercise price and number of shares underlying outstanding stock options and warrants.

5The par value of the Common Stock and the authorized number of shares remain unchanged.

6The amendment was approved by stockholders on February 20, 2026, and filed with the Delaware Secretary of State on March 25, 2026.

Current Report Details

Event Type

Securities Modification

Charter Amendment

Exhibits

Disclosure

Mandatory

Variant

8-K

Items Reported

3.03

Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defi

Securities Modification

5.03

of this Current Report on Form 8-K is incorporated by reference herein. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On M

Charter Amendment

9.01

Financial Statements and Exhibits. | Exhibit 3.1 | | Amendment to Amended and Restated Certificate of Incorporation, as amended | |---|---|---| | Exhibit 104 |

Exhibits Only

Exhibits (2)

3.1

EX-3.1

8-K